申请人:INTRA CELLULAR THERAPIES INC
公开号:WO2009073210A1
公开(公告)日:2009-06-11
1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[lH, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful for the treatment of diseases involving disorders of the dopamine Dl receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone - signaling pathway, e.g., female sexual dysfunction.
1-或2-或7-(取代)-3-(可选杂)芳基氨基-[1H, 2H]-吡唑[3,4-d]吡嘧啶-4,6(5H, 7H)-二酮衍生物,以自由、盐或前药形式存在,可用作药物,特别是磷酸二酯酶1抑制剂,用于治疗涉及多巴胺D1受体细胞内通路紊乱的疾病,如帕金森病、抑郁症、嗜睡症和损害认知功能,例如精神分裂症或可以通过增强孕酮-信号通路改善的疾病,例如女性性功能障碍。